A Phase 1, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies

Trial Profile

A Phase 1, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2014

At a glance

  • Drugs Ganetespib (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Synta Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2012 Updated results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a Synta Pharmaceuticals media release.
    • 17 May 2012 Updated results will be presented at ASCO-2012 according to a Synta Pharmaceuticals media release.
    • 27 Sep 2011 Results were presented at the European Multidisciplinary Cancer Congress (ECC-ESMO) in September 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top